Allogene reports Q4 net loss $85.8M, cash $448.7M; ALPHA3 trial to start mid-2024

Allogene Therapeutics, Inc.

Net loss Q4 2023 $85.8M ($0.51/share); full-year net loss $327.3M ($2.09/share).
Cash, cash equivalents & investments $448.7M as of Dec 31, 2023; cash runway into 2026 reaffirmed.
2024 GAAP op. expenses ~$280M; expected cash burn ~$190M; non-cash comp ~$60M.
Pivotal cema-cel ALPHA3 1L LBCL trial enrollment begins mid-2024; randomized 230 MRD+ patients.
ALLO-329 (CD19 Dagger) for autoimmune disease to enter Phase 1 in early 2025; Arbor Biotechnologies licensing deal.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Allogene Therapeutics, Inc. reported financial results for fourth quarter and year ended December 31, 2023.

Period: fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 14, 2024, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the fourth quarter and year ended December 31, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-24-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.